LGND
Ligand Pharmaceuticals Incorporated
298.40$
+0.0%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +102.9% | +51.0% | +48.5% | +107.4% | -115.1% | – | +44.4% | +74.9% | -64.0% | +95.8% | -49.1% | |
| – | -1.1% | +329.8% | +3.8% | +25.6% | +197.1% | -36.0% | +82.2% | +0.8% | -28.9% | -3.5% | +1.4% | |
| – | +10.5% | +51.7% | +31.9% | -16.3% | +17.6% | +25.3% | +26.2% | +55.4% | -57.3% | +59.6% | +14.0% | |
| – | -2,228.9% | – | +35.9% | -87.6% | -8,009.5% | – | – | +674.5% | – | – | – | |
| – | – | -1,393.5% | – | – | – | – | – | – | -152.4% | – | -165.4% | |
| – | +141.5% | +160.7% | -74.7% | +66.2% | -78.5% | +74.6% | +96.5% | +104.6% | +200.4% | -63.5% | -97.7% | |
| – | +5,467.9% | +26.9% | -41.2% | +402.8% | – | -50.4% | -86.8% | +436.1% | -107.1% | +1,129.8% | +162.6% | |
| – | – | – | – | – | – | +0.7% | +407.7% | -67.3% | – | – | – | |
| – | -99.3% | +697.8% | -49.6% | +6,149.6% | +268.7% | -82.8% | -76.4% | -55.4% | -44.8% | +13.0% | +192.1% | |
| – | – | +0.0% | +0.0% | -3.2% | -105.3% | +713.3% | -25.8% | +58.2% | -70.5% | -100.0% | – | |
| – | -93.6% | -81.9% | -596.6% | – | -247.7% | -36.0% | -55.6% | +100.3% | -78.3% | – | +340.8% | |
| – | -142.3% | – | – | +5,208.4% | -147.9% | – | – | – | -186.5% | – | +107.9% | |
| – | +92.1% | +12.4% | +149.2% | +110.8% | -117.5% | – | +39.7% | +71.2% | -103.6% | – | -36.8% |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.